Purple Biotech Ltd (PPBT)
NASDAQ: PPBT · Real-Time Price · USD
1.490
+0.150 (11.19%)
At close: Nov 11, 2026, 4:00 PM EST
1.500
+0.010 (0.67%)
After-hours: Nov 11, 2026, 4:27 PM EST
Purple Biotech Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
10
Market Cap
10.49M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Palatin Technologies | 13.19M |
| Radiopharm Theranostics | 8.90M |
| SeaStar Medical Holding | 1.71M |
| CytoMed Therapeutics | 609.73K |
| Vyome Holdings | 129.73K |
| Lisata Therapeutics | 100.00K |
PPBT News
- 13 days ago - Purple Biotech Announces IM1240 Abstract Selected for Oral Presentation at the 38th EORTC-NCI-AACR Symposium - GlobeNewsWire
- 2 months ago - Why Is Purple Biotech (PPBT) Stock 42% Up Today? - TipRanks
- 2 months ago - Purple Biotech issued notice of allowance from USPTO - TheFly
- 2 months ago - New U.S. Patent Allowance Strengthens Protection for CAPTN-3 Modular Platform for Next-Generation Multispecific Antibodies - GlobeNewsWire
- 3 months ago - Purple Biotech price target lowered to $17 from $30 at H.C. Wainwright - TheFly
- 5 months ago - Purple Biotech presents new IM1240 data at EACR - TheFly
- 5 months ago - Purple Biotech files $200M mixed securities shelf - TheFly
- 6 months ago - Purple Biotech reports IM1240 demonstrates potent anti-tumor activity - TheFly